Simple sputum test could catch lung cancer early

NCT ID NCT07168993

Recruiting now Diagnosis Sponsor: bioAffinity Technologies Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times

Summary

This study is testing a new test called FlowPath Lung that looks for early-stage lung cancer in sputum (phlegm). The test is for people at high risk for lung cancer who have a lung nodule between 6 and 30 mm. The goal is to see how well the test can find cancer compared to standard methods. About 2063 participants will provide a sputum sample for analysis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Audie Murphy VA Medical Center
RECRUITING

San Antonio, Texas, 78234, United States
Brooke Army Medical Center
RECRUITING

San Antonio, Texas, 78234, United States
Clinical Research Associates of Central Pennsylvania
RECRUITING

DuBois, Pennsylvania, 15801, United States

Conditions

Explore the condition pages connected to this study.

LUNG CANCER (DIAGNOSIS)